Author:
Murphy D M,Bejar R,Stevenson K,Neuberg D,Shi Y,Cubrich C,Richardson K,Eastlake P,Garcia-Manero G,Kantarjian H,Ebert B L,Mike Makrigiorgos G
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference15 articles.
1. Jadersten M . Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion. Haematologica 2010; 95: 348–351.
2. Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ et al. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. J Natl Compr Canc Netw 2011; 9: 30–56.
3. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496–2506.
4. Bejar R, Ebert BL . The genetic basis of myelodysplastic syndromes. Hematol Oncol Clin N Am 2010; 24: 295–315.
5. Fidler C, Watkins F, Bowen DT, Littlewood TJ, Wainscoat JS, Boultwood J . NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica 2004; 89: 865–866.
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献